These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38664020)

  • 1. MRI and
    Rosen J; Werner JM; Ceccon GS; Rosen EK; Wollring MM; Stetter I; Lohmann P; Mottaghy FM; Fink GR; Langen KJ; Galldiks N
    J Nucl Med; 2024 Jun; 65(6):838-844. PubMed ID: 38664020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost Effectiveness of
    Rosen J; Ceccon G; Bauer EK; Werner JM; Tscherpel C; Dunkl V; Rapp M; Sabel M; Herrlinger U; Heinzel A; Schäfer N; Ruge M; Goldbrunner R; Stoffels G; Kabbasch C; Fink GR; Langen KJ; Galldiks N
    J Nucl Med; 2022 Nov; 63(11):1677-1682. PubMed ID: 35422443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis.
    Heinzel A; Müller D; Langen KJ; Blaum M; Verburg FA; Mottaghy FM; Galldiks N
    J Nucl Med; 2013 Aug; 54(8):1217-22. PubMed ID: 23785172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. O-(2-18F-fluoroethyl)-L-tyrosine PET for evaluation of brain metastasis recurrence after radiotherapy: an effectiveness and cost-effectiveness analysis.
    Heinzel A; Müller D; Yekta-Michael SS; Ceccon G; Langen KJ; Mottaghy FM; Wiesmann M; Kocher M; Hattingen E; Galldiks N
    Neuro Oncol; 2017 Sep; 19(9):1271-1278. PubMed ID: 28204572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of FET PET-guided target selection for the diagnosis of gliomas.
    Heinzel A; Stock S; Langen KJ; Müller D
    Eur J Nucl Med Mol Imaging; 2012 Jul; 39(7):1089-96. PubMed ID: 22419257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Monitoring of Immunotherapy and Targeted Therapy Using
    Galldiks N; Abdulla DSY; Scheffler M; Wolpert F; Werner JM; Hüllner M; Stoffels G; Schweinsberg V; Schlaak M; Kreuzberg N; Landsberg J; Lohmann P; Ceccon G; Baues C; Trommer M; Celik E; Ruge MI; Kocher M; Marnitz S; Fink GR; Tonn JC; Weller M; Langen KJ; Wolf J; Mauch C
    J Nucl Med; 2021 Apr; 62(4):464-470. PubMed ID: 32887757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.
    Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-FET PET for Diagnosis of Pseudoprogression of Brain Metastases in Patients With Non-Small Cell Lung Cancer.
    Akhoundova D; Hiltbrunner S; Mader C; Förster R; Kraft J; Schwanhäusser B; Bankel L; Kollias S; Treyer V; Rushing EJ; Lee SY; Andratschke N; Hüllner M; Curioni-Fontecedro A
    Clin Nucl Med; 2020 Feb; 45(2):113-117. PubMed ID: 31876831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The positive predictive value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment.
    Mehrkens JH; Pöpperl G; Rachinger W; Herms J; Seelos K; Tatsch K; Tonn JC; Kreth FW
    J Neurooncol; 2008 May; 88(1):27-35. PubMed ID: 18217207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI.
    Galldiks N; Langen KJ; Holy R; Pinkawa M; Stoffels G; Nolte KW; Kaiser HJ; Filss CP; Fink GR; Coenen HH; Eble MJ; Piroth MD
    J Nucl Med; 2012 Jul; 53(7):1048-57. PubMed ID: 22645298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of
    Brendle C; Maier C; Bender B; Schittenhelm J; Paulsen F; Renovanz M; Roder C; Castaneda-Vega S; Tabatabai G; Ernemann U; Fougère C
    J Nucl Med; 2022 Apr; 63(4):522-527. PubMed ID: 34353870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.
    Hutterer M; Nowosielski M; Putzer D; Waitz D; Tinkhauser G; Kostron H; Muigg A; Virgolini IJ; Staffen W; Trinka E; Gotwald T; Jacobs AH; Stockhammer G
    J Nucl Med; 2011 Jun; 52(6):856-64. PubMed ID: 21622893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined FET PET/MRI radiomics differentiates radiation injury from recurrent brain metastasis.
    Lohmann P; Kocher M; Ceccon G; Bauer EK; Stoffels G; Viswanathan S; Ruge MI; Neumaier B; Shah NJ; Fink GR; Langen KJ; Galldiks N
    Neuroimage Clin; 2018; 20():537-542. PubMed ID: 30175040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging of amino acid transport in brain tumours: Positron emission tomography with O-(2-[
    Langen KJ; Stoffels G; Filss C; Heinzel A; Stegmayr C; Lohmann P; Willuweit A; Neumaier B; Mottaghy FM; Galldiks N
    Methods; 2017 Nov; 130():124-134. PubMed ID: 28552264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic impact of additional O-(2-[18F]fluoroethyl)-L-tyrosine (
    Kristin Schmitz A; Sorg RV; Stoffels G; Grauer OM; Galldiks N; Steiger HJ; Kamp MA; Langen KJ; Sabel M; Rapp M
    Br J Neurosurg; 2021 Dec; 35(6):736-742. PubMed ID: 31407920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [
    Pruis IJ; Verburg FA; Balvers RK; Harteveld AA; Feelders RA; Vernooij MW; Smits M; Neggers SJCMM; Veldhuijzen van Zanten SEM
    J Nucl Med; 2024 May; 65(5):688-692. PubMed ID: 38514085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases.
    Grosu AL; Astner ST; Riedel E; Nieder C; Wiedenmann N; Heinemann F; Schwaiger M; Molls M; Wester HJ; Weber WA
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1049-58. PubMed ID: 21570201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron emission tomography/computerised tomography imaging in detecting and managing recurrent cervical cancer: systematic review of evidence, elicitation of subjective probabilities and economic modelling.
    Meads C; Auguste P; Davenport C; Małysiak S; Sundar S; Kowalska M; Zapalska A; Guest P; Thangaratinam S; Martin-Hirsch P; Borowiack E; Barton P; Roberts T; Khan K
    Health Technol Assess; 2013 Mar; 17(12):1-323. PubMed ID: 23537558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of recurrent high-grade glioma using microstructure characteristics of distinct metabolic compartments in a multimodal and integrative 18F-FET PET/fast-DKI approach.
    Lohmeier J; Radbruch H; Brenner W; Hamm B; Hansen B; Tietze A; Makowski MR
    Eur Radiol; 2024 Apr; 34(4):2487-2499. PubMed ID: 37672058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of Dynamic O-(2-[
    Lohmann P; Piroth MD; Sellhaus B; Weis J; Geisler S; Oros-Peusquens AM; Mohlberg H; Amunts K; Shah NJ; Galldiks N; Langen KJ
    World Neurosurg; 2018 Nov; 119():e653-e660. PubMed ID: 30077752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.